Company Filing History:
Years Active: 2008-2013
Title: Innovations and Patents of John Frederick Braganza
Introduction: John Frederick Braganza, an accomplished inventor based in San Diego, CA, has made significant contributions to the field of pharmaceutical sciences. With a total of two patents to his name, his innovative work serves as a testament to his expertise and dedication in developing novel compounds that address critical health issues.
Latest Patents: Among his latest patented inventions are "6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors." This patent specifically focuses on compounds designed to inhibit CHK-1, along with their synthesis and potential applications in medicine. Additionally, Braganza has developed "triazolo-pyridines as anti-inflammatory compounds," which details the synthesis of a new class of triazolo-pyridines, promising advancements in anti-inflammatory therapies.
Career Highlights: John Frederick Braganza is currently affiliated with Pfizer Corporation, a leading global pharmaceutical company known for its commitment to research and development. His role at Pfizer allows him to explore innovative solutions and contribute to the development of effective medications that can improve patient outcomes.
Collaborations: Throughout his career, Braganza has collaborated with esteemed colleagues, including Michael Raymond Collins and John Charles Kath. Their collective expertise and collaborative efforts have facilitated the advancement of research projects within the pharmaceutical domain.
Conclusion: John Frederick Braganza's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents not only showcase his inventiveness but also highlight the importance of collaboration in driving significant advancements in medical research. As he continues to develop new compounds, his contributions will undoubtedly impact healthcare and treatment options for patients worldwide.